注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Scholar Rock Holding Corp是一家专注于发现和开发治疗严重疾病的药物的生物制药公司。该公司的候选产品包括apitegromab,apitegromab是一种激活潜在肌生长抑制素的抑制剂,用于治疗脊髓性肌萎缩(SMA),并用于治疗其他肌生长抑制素相关疾病。其候选产品还包括SRK-181,SRK-181是一种激活潜在转化生长因子β1(TGFβ1)的抑制剂,用于治疗抗PD-(L)1抗体疗法耐药的癌症。其选择性抑制剂激活转化生长因子β(TGFβ),用于治疗纤维化疾病。它正在推进多种抗体图谱的产品候选选择,包括在纤维化细胞外基质中选择性抑制潜在TGFβ1激活的抗体,以及避免干扰免疫系统细胞呈现的TGFβ1的抗体。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
David L. Hallal | 55 | 2017 | Independent Chairman of the Board |
Lynn Sakai | - | - | Member of Scientific Advisory Board |
Kristina M. Burow | 49 | 2014 | Independent Director |
Akshay K. Vaishnaw | 59 | 2014 | Independent Director & Member of Scientific Advisory Board |
Jeffrey S. Flier | 74 | 2016 | Independent Director & Member of Scientific Advisory Board |
Joshua Reed | 49 | 2021 | Independent Director |
Timothy A. Springer | 74 | 2012 | Member of Scientific Advisory Board |
Michael Gilman | 67 | 2013 | Independent Director & Member of Scientific Advisory Board |
Leonard I. Zon | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Barry S. Coller | - | - | Member of Scientific Advisory Board |
Joan Massague | 69 | - | Member of Scientific Advisory Board |
Daniel B. Rifkin | - | - | Member of Scientific Advisory Board |
Amir H. Nashat | 49 | 2012 | Independent Director |
Shelia M. Violette | - | - | Member of Scientific Advisory Board |
Srinivas Akkaraju | 54 | 2022 | Independent Director |
Richard Brudnick | 66 | 2023 | Independent Director |
Jay T. Backstrom | 68 | 2022 | President, CEO & Director |
Katie Peng | - | 2024 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核